Skip to main content

Table 1 Association of the patients’ clinical parameters with NLR and PLR

From: The prognostic significance of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in giant cell tumor of the extremities

clinical parameters total NLR p-value PLR p-value
LNLR (n = 113) HNLR (n = 50) LPLR (n = 90) HPLR (n = 73)
age (year) 38.49 ± 11.10 38.29 ± 11.18 38.94 ± 11.03 0.732 39.07 ± 10.48 37.78 ± 11.86 0.464
Sex
 Male 91 63 28 0.977 49 42 0.693
 Female 72 50 22   41 31  
Companacci stage
 I-II stage 86 70 16 < 0.001 59 27 < 0.001
 III stage 77 43 34   31 46  
tumor diameter (cm) 5 (4~7) 5 (4~6) 6 (5~8) 0.048 5 (4~6) 6 (5~8) 0.006
ALP(U/L) 79 (63~122) 76 (62~121) 98 (64~136) 0.047 73 (59~107) 91 (68~124) 0.008
white blood cell (109/L) 6.03 (5.12~7.06) 6.01 (5.13~6.79) 6.20 (5.04~7.30) 0.450 5.95 (5.05~7.06) 6.20 (5.15~7.04) 0.544
neutrophil (%) 55.4 (50.0~61.6) 52.6 (47.8~56.2) 63.6 (61.4~68.4 < 0.001 54.6 (48.8~60.7) 57.1 (50.6~63.2) 0.120
lymphocytes(%) 29.5 (24.2~36.6) 33.8 (29.2~38.9) 22.2 (18.9~24.3) < 0.001 31.1 (25.6~37.1) 28.2 (23.8~34.2) 0.117
platelet (109/L) 232 (195~272) 231 (191~266) 246 (200~290) 0.159 203 (165~235) 274 (242~314) < 0.001
ESR (mm/h) 17 (9~34) 16 (9~34) 19 (10~36) 0.439 16 (8~37) 21 (10~34) 0.471
CRP (mg/L) 8.16 (3.77~13.57) 7.64 (3.65~11.93) 12.51 (4.05~23.38) 0.043 6.52 (3.44~11.89) 10.59 (4.39~25.85) 0.005
  1. ALP, alkaline phosphatase; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio
\